---
title: "ABIVAX Société Anonyme (ABVX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ABVX.US.md"
symbol: "ABVX.US"
name: "ABIVAX Société Anonyme"
industry: "Biotechnology"
datetime: "2026-05-21T17:30:19.862Z"
locales:
  - [en](https://longbridge.com/en/quote/ABVX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ABVX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ABVX.US.md)
---

# ABIVAX Société Anonyme (ABVX.US)

## Company Overview

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.abivax.com](https://www.abivax.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: D (0.69)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 203 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -60.62% |  |
| Net Profit YoY | -104.22% |  |
| P/B Ratio | 17.87 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9555374746.50 |  |
| Revenue | 5265625.12 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -135.58% | E |
| Profit Margin | -7354.53% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -60.62% | E |
| Net Profit YoY | -104.22% | E |
| Total Assets YoY | 221.51% | A |
| Net Assets YoY | 1166.55% | A |
| Cash Flow Margin | 47.94% | C |
| OCF YoY | -60.62% | E |
| Turnover | 0.01 | E |
| Gearing Ratio | 22.10% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - ABIVAX Société Anonyme",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-60.62%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-104.22%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "17.87",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "9555374746.50",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5265625.12",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-135.58%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-7354.53%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-60.62%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-104.22%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "221.51%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "1166.55%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "47.94%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-60.62%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "22.10%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -24.67 | 511/385 | - | - | - |
| PB | 17.87 | 412/385 | 17.62 | 16.05 | 14.80 |
| PS (TTM) | 1814.67 | 297/385 | 1652.24 | 1258.55 | 460.08 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 60% |
| Overweight | 4 | 40% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 122.72 |
| Highest Target | 176.00 |
| Lowest Target | 131.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ABVX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ABVX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ABVX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ABVX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**